Physician profile
Deepa Srinivasan
NPI 1326214545
$2,303.03
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $338 · 2021: $12.34 · 2022: $1,474 · 2023: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $494.56 | 2020-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $277.63 | 2020-2023 | Farxiga |
| Abbvie INC. | $272.67 | 2022 | |
| Esperion Therapeutics, INC. | $147.78 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.56 | 2022-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $113.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $105.83 | 2022-2023 | |
| Lilly USA, LLC | $91.00 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $85.92 | 2022-2023 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $73.84 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.05 | 2022-2023 | Xifaxan |
| Dexcom, INC. | $69.89 | 2022-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $58.70 | 2022 | |
| Merck Sharp & Dohme LLC | $44.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.22 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.34 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $31.50 | 2022-2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.67 | 2022 | |
| Dermira, INC. | $27.50 | 2020 | |
| Pfizer INC. | $22.47 | 2023 | |
| Abbott Laboratories | $21.89 | 2023 | Freestyle Libre 2 |
| Amgen INC. | $20.62 | 2023 | Repatha |
| Mylan Specialty L.P. | $20.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.